Short‐term effects of the TNFα antagonist infliximab on the acute phase reaction and activities of daily life in patients with rheumatoid arthritis

References

• Charles P., Elliot M. J., Davis D., Potter A., Kalden J. R., Antoni C., et al. Regulation of cytokines, cytokine inhibitors, and acute‐phase proteins following anti‐TNF‐α therapy in rheumatoid arthritis. J Immunol 1999; 163: 1521–8
   PubMed Web of Science ®Google Scholar
• Richardson C., Emery P. Laboratory markers of disease activity. J Rheumatol 1996; Suppl 44: 23–30
   Google Scholar
• Wolfe F. Comparative usefulness of C‐reactive protein and erythrocyte sedimentation rate in patients with rheumatoid arthritis. J Rheumatol 1997; 24: 1477–85
   PubMed Web of Science ®Google Scholar
• Ward M. M. Relative sensitivity to change of the erythrocyte sedimentation rate and serum C‐reactive protein concentration in rheumatoid arthritis. J Rheumatol 2004; 31: 884–95
   PubMed Web of Science ®Google Scholar
• Weinblatt M. E., Keystone E. C., Furst D. E., Moreland L. W., Weisman M. H. B., Birbara C. A. Adalimumab, a fully human anti‐tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate. Arthritis Rheum 2003; 48: 35–45
   PubMed Web of Science ®Google Scholar
• Arvidson N. G., Larsson A., Larsen A. Disease activity in rheumatoid arthritis: fibrinogen is superior to the erythrocyte sedimentation rate. Scand J Clin Lab Invest 2002; 62: 315–20
   PubMed Web of Science ®Google Scholar
• Pollmacher T., Haack M., Schuld A., Reichenberg A., Yirmiya R. Low levels of circulating cytokines – Do they affect human brain functions?. Brain Behav Immun 2002; 16: 525–32
   PubMed Web of Science ®Google Scholar
• Zamarrón C., Maceiras F., Mera A., Gómez‐Reino J. J. Effect of the first infliximab infusion on sleep and alertness in patients with active rheumatoid arthritis. Ann Rheum Dis 2004; 63: 88–90
   PubMed Web of Science ®Google Scholar
• Fries J. F., Spitz P. W., Kraines R. G., Holman H. R. Measurement of patients' outcome in arthritis. Arthritis Rheum 1980; 23: 137–45
   PubMed Web of Science ®Google Scholar
• Cohen J. Statistical power analysis for the behavioral sciences. Lawrence Earlbaum Associates, Hillsdale, NJ 1988
   Google Scholar
• Larsen A. How to apply Larsen score in evaluating radiographics of rheumatoid arthritis in long‐term studies. J Rheumatol 1995; 22: 1974–5
   PubMed Web of Science ®Google Scholar
• Torikai E., Kageyama Y., Takahashi M., Suzuki M., Ichikawa T., Nagafusa T., et al. The effect of infliximab on bone metabolism markers in patients with rheumatoid arthritis. Rheumatology 2006; 45: 761–4
   PubMed Web of Science ®Google Scholar
• Klimiuk P. A., Sierakowsky S., Domyslawska I., Fiedorczyk M., Chwiecko J. Reduction of soluble adhesion molecyles (sICAM‐1, sVCAM‐1 and sE‐selectin) and vascular endothelial growth factor levels in serum of rheumatoid arthritis patients following multiple intravenous infusions of infliximab. Arch Immunol Ther Exp 2004; 52: 36–42
   PubMed Web of Science ®Google Scholar
• Bowman S. J. Hematological manifestations of rheumatoid arthritis. Scand J Rheumatol 2002; 31: 251–9
   PubMed Web of Science ®Google Scholar
• Matteson E. L. Extra‐articular features of rheumatoid arthritis and systemic involvement. Rheumatology, M. C Hochberg, A. J Silman, J. S Smolen, M. E Weinblatt, M. H Weisman. Mosby, Edinburgh 2003; 781–92
   Google Scholar
• Saag K. G., Criswell L. A., Sems K. M., Nettleman M. D., Kolluri S. Low‐dose corticosteroids in rheumatoid arthritis. A meta‐analysis of their moderate‐term effectiveness. Arthritis Rheum 1996; 39: 1818–25
   PubMed Web of Science ®Google Scholar
• Jacobs J. W. G., Geenen R., Evers A. W. M., van Jaarsveld C. H. M., Kraaimaat F. W., Bijlsma J. W. J. Short term effects of corticosteroid pulse treatment on disease activity and the wellbeing of patients with active rheumatoid arthritis. Ann Rheum Dis 2001; 60: 61–4
   PubMed Web of Science ®Google Scholar
• Buch M. H., Seto Y., Bingham S. J., Bejarano V., Bryer D., White Jo., et al. C‐reactive protein as a predictor of infliximab treatment outcome in patients with rheumatoid arthritis. Arthritis Rheum 2005; 52: 42–8
   PubMed Web of Science ®Google Scholar
• Kannel W. B., Wolf P. A., Castelli W. P., D'Agostino R. B. Fibrinogen and risk of cardiovascular disease. The Framingham study. J Am Med Assoc 1987; 258: 1183–6
   PubMed Web of Science ®Google Scholar
• Sjöblom K. G., Saxne T., Pettersson H., Wollheim F. A. Factors related to the progression of joint destruction in rheumatoid arthritis. Scand J Rheumatol 1984; 13: 21–7
   PubMed Web of Science ®Google Scholar
• Scott D. L., Strand V. The effects of disease‐modifying anti‐rheumatic drugs on the Health Assessment Questionnaire score. Lessons from the leflunomide clinical studies database. Rheumatology 2002; 41: 899–909
   PubMedGoogle Scholar